DMD clinical trial

Santhera Pharmaceuticals is conducting a phase 3 trial of the antioxidant idebenone in Duchenne muscular dystrophy

posted on December 15, 2010 - 11:22am
A large-scale, phase 3 trial of idebenone (Catena) in Duchenne muscular dystrophy (DMD) is now open at one U.S. site and several sites in Europe, under the auspices of Santhera Pharmaceuticals.

A study of exon-skipping drug GSK2402968 in nonambulatory subjects with DMD has opened at Nationwide Children's Hospital in Ohio

posted on June 18, 2010 - 11:58am
Update (Nov. 5, 2012): Results announced in November 2012 showed the drug, now called drisapersen, reached blood levels approximately proportional to the injected dose at two of the three dosage levels tested and was not associated with serious adverse events. See Drisapersen Appears Safe in Non-Walking Boys With DMD.